| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Hypertension. 2004;44:387.)
© 2004 American Heart Association, Inc.
Special Report |
From the Department of Medicine (B.F.), Thomas Jefferson University, Philadelphia, Pa, and Cincinnati Childrens Hospital Medical Center (S.R.D.), Cincinnati, Ohio.
Correspondence to Bonita Falkner, MD, 833 Chestnut St, Suite 700, Philadelphia, PA 19107. E-mail Bonita.Falkner{at}jefferson.edu
| Introduction |
|---|
|
|
|---|
| Definition of Hypertension |
|---|
|
|
|---|
95th percentile for gender, age, and height on 3 or more separate occasions. Blood pressure levels that are
90th percentile but <95th percentile is now termed "prehypertension." The adult definition of prehypertension is used for adolescents because the 90th percentile for systolic blood pressure is >120 mm Hg by age 12 years. Adolescents with blood pressure
120/80 mm Hg (but <95th percentile) have prehypertension. The Fourth Report has added a method for staging the severity of hypertension by providing the range of blood pressure elevation for stage 1 and stage 2 hypertension. Stage 2 hypertension is generally
12 mm Hg or more above the 95th percentile and represents a level of blood pressure that should result in further evaluation within 1 week or immediately if the patient is symptomatic. | Measurement of Blood Pressure in Children |
|---|
|
|
|---|
| Blood Pressure Tables |
|---|
|
|
|---|
Appendix material in the report contains information that can be useful for research purposes. An appendix provides the demographic data on the source and sample size of all pediatric age cohorts that have been entered into the entire blood pressure database. An additional appendix contains the equations necessary to compute blood pressure percentiles and blood pressure Z scores for individual subjects. This will allow investigators to compare blood pressures across age, height, and sex groups.
| Evaluation of Hypertension in Children |
|---|
|
|
|---|
The childhood obesity epidemic4 appears to be associated with higher blood pressure in childhood5 and earlier expression of primary hypertension. Therefore, the Working Group recommends that children with hypertension also be evaluated for comorbidity or associated risk factors. These comorbidities include, particularly in children who are also overweight, blood lipid abnormalities, abnormal glucose tolerance, sleep disorders, and substance abuse. A fasting lipid panel is recommended for overweight children with prehypertension and all children with hypertension. The extent of screening for diabetes or prediabetes may be determined by family history of diabetes and physical examination (eg, acanthosis nigricans). Initial screening for sleep disorders or substance abuse can be achieved by medical history, with the need for additional studies determined by the response to questions regarding sleep problems or suspicion of substance abuse. An evaluation for target-organ injury is recommended for children with hypertension and also for children who have prehypertension and comorbid risk factors. Based on evidence that at least 25% of hypertensive children have left ventricular hypertrophy, an echocardiogram should be performed in the evaluation to determine whether left ventricular hypertrophy is present in a hypertensive child.
| Treatment of Hypertension in Children |
|---|
|
|
|---|
The number of antihypertensive drugs that have been studied in children has increased since the last update on high blood pressure in children. The available pediatric data on antihypertensive drugs were examined by the Working Group, and tables that contain the most current dosing recommendations for antihypertensive drugs in children aged 16 years or younger are provided in the report. Indications for antihypertensive drug therapy in children include secondary hypertension and insufficient response to lifestyle modifications. Specific indications are detailed in the report. Pharmacological therapy, when indicated, should be initiated with a single drug. Acceptable drug classes for use in children include angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, ß adrenergic blockers, calcium channel blockers, and diuretics. The goal for antihypertensive treatment in children should be reduction of blood pressure to <95th percentile unless concurrent conditions are present, such as chronic renal disease and diabetes, in which case the blood pressure should be lowered to <90th percentile. Severe symptomatic hypertension should be treated with intravenous antihypertensive drugs. The Fourth Report includes a table of pharmacological agents that are preferred for use in pediatric patients with severe hypertension requiring more urgent lowering of blood pressure.
A conservative estimate is that
1% to 3% of individuals in the pediatric age range of <18 years have hypertension, and considerable more young persons in this age range have prehypertension. There is concern that with increasing overweight in the population, this prevalence may increase. It is often difficult to determine which of these children require extensive evaluation and intense treatment versus those cases in which more focus should be placed on lifestyle change and monitoring. A management algorithm is provided in the report that summarizes the monitoring, evaluation, and intervention guidelines for children and adolescents with prehypertension, stage 1 hypertension, and stage 2 hypertension. Included in the algorithm are points at which the presence of overweight is considered in clinical decision-making. The information provided in the Fourth Report on Diagnosis, Evaluation, and Treatment of High Blood Pressure in Children and Adolescents should encourage and facilitate clinical efforts to identify and manage hypertension in the young and reduce risk for future cardiovascular events.
Received August 12, 2004; first decision August 16, 2004; accepted August 19, 2004.
| References |
|---|
|
|
|---|
2. National High Blood Pressure Education Program Working Group on Hypertension Control in Children and Adolescents. Update on the 1987 task force report on high blood pressure in children and adolescents: a working group report from the National High Blood Pressure Education Program. Pediatrics. 1996; 98: 649658.
3. Centers for Disease Control and Prevention. National Center for Health Statistics. 2000 CDC growth charts: United States. Available at: www. cdc.gov/growthcharts. Accessed March 18, 2004.
4. Ogden CL, Flegal KM, Carroll MD, Johnson CL. Prevalence and trends in overweight among US children and adolescents, 19992000. JAMA. 2002; 288: 17281732.
5. Munter P, He J, Cutler JA, Wildman RP, Whelton PK. Trends in blood pressure among children and adolescents. JAMA. 2004; 291: 21072113.
This article has been cited by other articles:
![]() |
K. B. Daratha and R. C. Bindler Effects of Individual Components, Time, and Sex on Prevalence of Metabolic Syndrome in Adolescents Arch Pediatr Adolesc Med, April 1, 2009; 163(4): 365 - 370. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. L. Liu, J. P. Yi, J. Beyer, E. J. Mayer-Davis, L. M. Dolan, D. M. Dabelea, J. M. Lawrence, B. L. Rodriguez, S. M. Marcovina, B. E. Waitzfelder, et al. Type 1 and Type 2 Diabetes in Asian and Pacific Islander U.S. Youth: The SEARCH for Diabetes in Youth Study Diabetes Care, March 1, 2009; 32(Supplement_2): S133 - S140. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Velasquez-Mieyer, C. P. Neira, R. Nieto, and P. A. Cowan Review: Obesity and cardiometabolic syndrome in children Therapeutic Advances in Cardiovascular Disease, October 1, 2007; 1(1): 61 - 81. [Abstract] [PDF] |
||||
![]() |
N. Cheung, F. M. A. Islam, S. M. Saw, A. Shankar, K. de Haseth, P. Mitchell, and T. Y. Wong Distribution and Associations of Retinal Vascular Caliber with Ethnicity, Gender, and Birth Parameters in Young Children Invest. Ophthalmol. Vis. Sci., March 1, 2007; 48(3): 1018 - 1024. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. E. Hall and on behalf of the Editors Hypertension: Update 2006 Hypertension, September 1, 2006; 48(3): 343 - 346. [Full Text] [PDF] |
||||
![]() |
R. Shroff, D. J. Roebuck, I. Gordon, R. Davies, S. Stephens, S. Marks, M. Chan, M. Barkovics, C. A. McLaren, V. Shah, et al. Angioplasty for Renovascular Hypertension in Children: 20-Year Experience Pediatrics, July 1, 2006; 118(1): 268 - 275. [Abstract] [Full Text] [PDF] |
||||
![]() |
A Grosso, F Veglio, M Porta, F M Grignolo, and T Y Wong Hypertensive retinopathy revisited: some answers, more questions Br. J. Ophthalmol., December 1, 2005; 89(12): 1646 - 1654. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. E. Hall and on behalf of the Editors Hypertension--Update 2005 Hypertension, March 1, 2005; 45(3): 316 - 318. [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Hypertension Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2004 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |